Biogen Inc. (BIIB): George A Scangos , Chief Executive Officer of Biogen Inc. sold 157 shares on May 25, 2016. The Insider selling transaction was reported by the company on May 27, 2016 to the Securities and Exchange Commission. The shares were sold at $280.00 per share for a total value of $43,960.00 , the company said in a SEC Form 4 Filing.
Other Insider transactions have been reported by the company according to SEC Form 4, on May 4, 2016, George A Scangos (Chief Executive Officer) sold 487 shares at $274.74 per share price.On Apr 7, 2016, Adam Koppel (EVP, Strategy and Bus. Dev.) sold 102 shares at $275.00 per share price.Also, On Feb 26, 2016, Alfred Sandrock (EVP CMO Neuro & Neurodegenerat) sold 183 shares at $261.90 per share price.On Dec 3, 2015, Adriana Karaboutis (EVP, Tech. and Bus. Solutions) sold 48 shares at $289.14 per share price.
Biogen Inc: On Wednesday, May 25, 2016 heightened volatility was witnessed in Biogen Inc which led to swings in the share price. The shares opened for trading at $273.73 and hit $280.07 on the upside , eventually ending the session at $279.7, with a gain of 2.48% or 6.76 points. The heightened volatility saw the trading volume jump to 17,96,363 shares. The 52-week high of the share price is $420.99 and the company has a market cap of $61,269 M . The 52-week low of the share price is at $242.07.
Biogen Inc. formerly Biogen Idec Inc. is a global biopharmaceutical company. The Company is focused on discovering developing manufacturing and delivering therapies for neurological autoimmune and hematologic disorders. The Company develops manufactures and markets products designed for the treatment of multiple sclerosis (MS) and hemophilia A and B. The Company’s marketed products include AVONEX PLEGRIDY TECFIDERA TYSABRI FAMPYRA for multiple sclerosis (MS) ALPROLIX for hemophilia B and ELOCTATE for hemophilia A among others. It also collaborates on the development and commercialization of RITUXAN (rituximab) which is a monoclonal antibody for the treatment of non-Hodgkin’s lymphoma chronic lymphocytic leukemia and other conditions and share profits and losses for GAZYVA which is for the treatment of chronic lymphocytic leukemia.